Such turbocharging will be based mostly on tax cuts and deregulation for the economy as a whole, and yet, of course, the subset that is the pharma industry will benefit as well.    Yet at the same time, we must observe that the pharmaceutical industry, closely regulated and scrutinized as it is, has special concerns.   And on Tuesday, Trump addressed those, too.   Even as he pledged to maintain safety standards, he pledged that his administration would be "focused on accelerating FDA approvals. . . . 